SKIN HEALING

NEMLUVIO delivered lasting skin healing in atopic dermatitis1

NEMLUVIO heals AD lesions to clear the skin2

Actual 26­-year­-old male patient at baseline with atopic dermatitis on arms and chest. Actual 26­-year­-old male patient at baseline with atopic dermatitis on arms and chest.
Actual 26­-year­-old male patient at Week 16 with improved atopic dermatitis on chest and arms. Actual 26­-year­-old male patient at Week 16 with improved atopic dermatitis on chest and arms.
 

Baseline

Week 16

26-YEAR-OLD MALE.
Actual patient.
Individual results 
may vary.*

26-YEAR-OLD MALE.
Actual patient. Individual results may vary.*

Actual 23­-year­-old male patient at baseline with atopic dermatitis on back of neck. Actual 23­-year­-old male patient at baseline with atopic dermatitis on back of neck.
Actual 23­-year­-old male patient at Week 16 with improved atopic dermatitis on back of neck. Actual 23­-year­-old male patient at Week 16 with improved atopic dermatitis on back of neck.
 

Baseline

Week 16

23-YEAR-OLD MALE.
Actual patient.
Individual results 
may vary.

23-YEAR-OLD MALE.
Actual patient. Individual results may vary.

Actual 13­-year­-old female patient at baseline with atopic dermatitis on legs. Actual 13­-year­-old female patient at baseline with atopic dermatitis on legs.
Actual 13­-year­-old female patient at Week 16 with improved atopic dermatitis on legs. Actual 13­-year­-old female patient at Week 16 with improved atopic dermatitis on legs.
 

Baseline

Week 16

13-YEAR-OLD 
FEMALE.
Actual patient.
Individual results 
may vary.

13-YEAR-OLD FEMALE.
Actual patient. Individual results may vary.

Actual 42­-year­-old male patient at baseline with atopic dermatitis on back and arms. Actual 42­-year­-old male patient at baseline with atopic dermatitis on back and arms.
Actual 42­-year­-old male patient at Week 16 with improved atopic dermatitis on back and arms. Actual 42­-year­-old male patient at Week 16 with improved atopic dermatitis on back and arms.
 

Baseline

Week 16

42-YEAR-OLD 
MALE.
Actual patient.
Individual results 
may vary.

42-YEAR-OLD MALE.
Actual patient. Individual results may vary.

26-year-old male.

23-year-old male.

13-year-old female.

42-year-old male.

REVIEW STUDY DESIGN 

Baseline IGA score was 4, and at Week 16, it had improved to 3.3

Previous

Next

44% of patients taking NEMLUVIO® + TCS/TCI achieved significantly clearer skin† vs 29% with placebo + TCS/TCI at Week 16 (P<0.0001)2,3‡

36% of patients taking NEMLUVIO + TCS/TCI achieved clear (IGA 0) or almost clear (IGA 1) skin vs 25% with placebo + TCS/TCI at Week 16 (P<0.001)2,3‡

Statistically significant clearance (EASI‑75) as early as Week 43§

Actor portrayal.

More than 8 out of 10 patients with AD achieved EASI-75 with over 2 years of treatment1

Patients with AD achieved EASI-75 with over 2 years of treatment.
Patients with AD achieved EASI-75 with over 2 years of treatment.

EASI-75 data for patients reaching 104 weeks during interim analysis of ARCADIA LTE.1

REVIEW STUDY DESIGN 

Favorable Safety Profile2

NEMLUVIO was well tolerated, has no boxed warning, and requires no preliminary lab evaluations or ongoing lab monitoring2

REVIEW SAFETY PROFILE 

Q4W Dosing From the Start2

NEMLUVIO is the only biologic approved for AD with Q4W dosing from the start2,5,6

LEARN MORE 

IMPORTANT SAFETY INFORMATION

INDICATIONS: NEMLUVIO® (nemolizumab-ilto) is an interleukin-31 receptor alpha antagonist indicated for:

  • the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies.
  • the treatment of adults with prurigo nodularis.

CONTRAINDICATION: NEMLUVIO is contraindicated in patients with known hypersensitivity to nemolizumab-ilto or to any of the excipients in NEMLUVIO.

WARNINGS AND PRECAUTIONS:
Hypersensitivity reactions have been reported with NEMLUVIO use. If clinically significant hypersensitivity reaction occurs, immediately institute appropriate therapy, and discontinue NEMLUVIO. Avoid use of live vaccines during treatment with NEMLUVIO.

ADVERSE REACTIONS:
Most common adverse reactions (incidence ≥1%) are:

  • Atopic Dermatitis: headache (including migraine), arthralgia, urticaria, and myalgia. 
  • Prurigo Nodularis: headache, dermatitis atopic, eczema, and eczema nummular. 

USE IN SPECIFIC POPULATIONS:
Pregnancy: There are no adequate and well-controlled studies on NEMLUVIO in pregnant women. The limited available information on NEMLUVIO use during pregnancy is not sufficient to inform a drug- associated risk of major birth defects or miscarriage in humans. Human IgG antibodies are known to cross the placental barrier; therefore, NEMLUVIO may be transmitted from the mother to the developing fetus.

Lactation: There are no data on the presence or transfer of NEMLUVIO in human milk, the effects on the breastfed infant, or the effects on milk production. Human IgG is known to be present in human milk. The effects of local gastrointestinal and limited systemic exposure to NEMLUVIO on the breastfed infant are unknown. NEMLUVIO has not been administered to nursing/lactating women. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for NEMLUVIO and any potential adverse effects on the breastfed child from NEMLUVIO or from the underlying maternal condition.

Pediatric Use: The safety and effectiveness of NEMLUVIO have not been established in pediatric patients younger than 12 years of age for the treatment of moderate-to-severe atopic dermatitis or pediatric patients younger than 18 years of age for the treatment of prurigo nodularis.

Please see full Prescribing Information, including Patient Information.